on January 17, 2005
Published online before print January 17, 2005, doi: 10.1161/01.CIR.0000153341.46271.40
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 22, 2004
From the Departments of Cardiology (S.M.B.), Vascular Medicine (G.J.d.G., J.A.K., J.J.P.K.), and Clinical Epidemiology and Biostatistics (A.H.Z.), Academic Medical Center, Amsterdam, the Netherlands; Nutrition Department (F.M.S.), Harvard School of Public Health, Boston, Mass; Department of Cardiology (J.W.J.), Leiden University Medical Center, Leiden, the Netherlands; Department of Pathological Biochemistry (J.S.), Glasgow Royal Infirmary, Glasgow, Scotland; Division of Developmental Medicine (D.J.F.) and Robertson Centre for Biostatistics (A.D.M.), University of Glasgow, Glasgow, Scotland; Institut National de la Santé et de la Recherche Médicale Unité 525 (V.N., F.C.), Paris, France; Division of Cardiovascular Genetics (P.J.T., S.E.H.), Department of Medicine, Royal Free and University College Medical School, London, England; MRC Cardiovascular Research Group (G.J.M.), Wolfson Institute of Preventive Medicine, St. Bartholomew’s and Royal London School of Medicine, London, England; Hjartavernd Research Institute (G.E., V.G.), Icelandic Heart Association, Kopavogur, Iceland; Department of Internal Medicine (H.K., S.K., M.J.S.), University of Oulu, Oulu, Finland; Department of Clinical and Applied Medical Therapy (M.A., A.M.), University of Rome La Sapienza, Rome, Italy; Division of Preventive Medicine (S.L.), Harvard Medical School and Brigham and Women’s Hospital, Boston, Mass; and Bristol-Myers Squibb Co (H.J.L.), Princeton, NJ. * To whom correspondence should be addressed. E-mail: e.vandongen{at}amc.uva.nl.
Background--Several studies have reported that the cholesteryl ester transfer protein (CETP) TaqIB gene polymorphism is associated with HDL cholesterol (HDL-C) levels and the risk of coronary artery disease (CAD), but the results are inconsistent. In addition, an interaction has been implicated between this genetic variant and pravastatin treatment, but this has not been confirmed. Methods and Results--A meta-analysis was performed on individual patient data from 7 large, population-based studies (each >500 individuals) and 3 randomized, placebo-controlled, pravastatin trials. Linear and logistic regression models were used to assess the relation between TaqIB genotype and HDL-C levels and CAD risk. After adjustment for study, age, sex, smoking, body mass index (BMI), diabetes, LDL-C, use of alcohol, and prevalence of CAD, TaqIB genotype exhibited a highly significant association with HDL-C levels, such that B2B2 individuals had 0.11 mmol/L (0.10 to 0.12, P<0.0001) higher HDL-C levels than did B1B1 individuals. Second, after adjustment for study, sex, age, smoking, BMI, diabetes, systolic blood pressure, LDL-C, and use of alcohol, TaqIB genotype was significantly associated with the risk of CAD (odds ratio=0.78 [0.66 to 0.93]) in B2B2 individuals compared with B1B1 individuals (P for linearity=0.008). Additional adjustment for HDL-C levels rendered a loss of statistical significance (P=0.4). Last, no pharmacogenetic interaction between TaqIB genotype and pravastatin treatment could be demonstrated. Conclusions--The CETP TaqIB variant is firmly associated with HDL-C plasma levels and as a result, with the risk of CAD. Importantly, this CETP variant does not influence the response to pravastatin therapy.
Revised on September 13, 2004
Accepted on September 24, 2004
Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment. Individual Patient Meta-Analysis of 13 677 Subjects
S. M. Boekholdt MD,
Key words: genetics • cholesterol • lipoproteins • coronary disease
Related Article:
Circulation 2005 111: 245.
This article has been cited by other articles:
 |
|
 |
|
  M. E. Keebler, C. L. Sanders, A. Surti, C. Guiducci, N. P. Burtt, and S. Kathiresan Association of Blood Lipids With Common DNA Sequence Variants at 19 Genetic Loci in the Multiethnic United States National Health and Nutrition Examination Survey III Circ Cardiovasc Genet, June 1, 2009; 2(3): 238 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Ridker, G. Pare, A. N. Parker, R. Y.L. Zee, J. P. Miletich, and D. I. Chasman Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction: Genomewide Analysis Among 18 245 Initially Healthy Women From the Women's Genome Health Study Circ Cardiovasc Genet, February 1, 2009; 2(1): 26 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pfeffer and F. M. Sacks Leapfrogging Data: No Shortcuts for Safety or Efficacy Information Circulation, December 9, 2008; 118(24): 2491 - 2494. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Nicholls, E. M. Tuzcu, D. M. Brennan, J.-C. Tardif, and S. E. Nissen Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) Circulation, December 9, 2008; 118(24): 2506 - 2514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Regieli, J. W. Jukema, D. E. Grobbee, J. J.P. Kastelein, J. A. Kuivenhoven, A. H. Zwinderman, Y. van der Graaf, M. L. Bots, and P. A. Doevendans CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction Eur. Heart J., November 2, 2008; 29(22): 2792 - 2799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Thompson, E. Di Angelantonio, N. Sarwar, S. Erqou, D. Saleheen, R. P. F. Dullaart, B. Keavney, Z. Ye, and J. Danesh Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk JAMA, June 18, 2008; 299(23): 2777 - 2788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. F. Wilson CETP Genes, Metabolic Effects, and Coronary Disease Risk JAMA, June 18, 2008; 299(23): 2795 - 2796. [Full Text] [PDF]
|
|
|
|
|
|
M. P. LaValley Logistic Regression Circulation, May 6, 2008; 117(18): 2395 - 2399. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kathiresan, O. Melander, D. Anevski, C. Guiducci, N. P. Burtt, C. Roos, J. N. Hirschhorn, G. Berglund, B. Hedblad, L. Groop, et al. Polymorphisms Associated with Cholesterol and Risk of Cardiovascular Events N. Engl. J. Med., March 20, 2008; 358(12): 1240 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Jensen, K. J. Mukamal, K. Overvad, and E. B. Rimm Alcohol consumption, TaqIB polymorphism of cholesteryl ester transfer protein, high-density lipoprotein cholesterol, and risk of coronary heart disease in men and women Eur. Heart J., January 1, 2008; 29(1): 104 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zeller, D. Masson, M. Farnier, L. Lorgis, V. Deckert, J.-P. Pais de Barros, C. Desrumaux, P. Sicard, J. Grober, D. Blache, et al. High Serum Cholesteryl Ester Transfer Rates and Small High-Density Lipoproteins Are Associated With Young Age in Patients With Acute Myocardial Infarction J. Am. Coll. Cardiol., November 13, 2007; 50(20): 1948 - 1955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Y Li, C. Zhang, F. W Asselbergs, L. Qi, E. Rimm, D. J Hunter, and F. B Hu Interaction between dietary fat intake and the cholesterol ester transfer protein TaqIB polymorphism in relation to HDL-cholesterol concentrations among US diabetic men Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1524 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Porchay-Balderelli, F. Pean, N. Bellili, R. Jaziri, M. Marre, F. Fumeron, and for the DIABHYCAR Study Group The CETP TaqIB Polymorphism Is Associated With the Risk of Sudden Death in Type 2 Diabetic Patients Diabetes Care, November 1, 2007; 30(11): 2863 - 2867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Singer, H. Holdaas, A. G. Jardine, B. Fellstrom, I. Os, G. Bermann, J. M. Meyer, and on behalf of the Assessment of Lescol in Renal Tra Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients J. Lipid Res., September 1, 2007; 48(9): 2072 - 2078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Cleophas and A. H. Zwinderman Meta-Analysis Circulation, June 5, 2007; 115(22): 2870 - 2875. [Full Text] [PDF]
|
|
|
|
|
|
D. K. Arnett, A. E. Baird, R. A. Barkley, C. T. Basson, E. Boerwinkle, S. K. Ganesh, D. M. Herrington, Y. Hong, C. Jaquish, D. A. McDermott, et al. Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease: A Scientific Statement From the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group Circulation, June 5, 2007; 115(22): 2878 - 2901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Horne, N. J. Camp, J. L. Anderson, C. P. Mower, J. L. Clarke, M. J. Kolek, J. F. Carlquist, and for the Intermountain Heart Collaborative Study Gr Multiple Less Common Genetic Variants Explain the Association of the Cholesteryl Ester Transfer Protein Gene With Coronary Artery Disease J. Am. Coll. Cardiol., May 22, 2007; 49(20): 2053 - 2060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. Ntzani, E. C. Rizos, and J. P. A. Ioannidis Genetic Effects versus Bias for Candidate Polymorphisms in Myocardial Infarction: Case Study and Overview of Large-Scale Evidence Am. J. Epidemiol., May 1, 2007; 165(9): 973 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Borggreve, H. L. Hillege, G. M. Dallinga-Thie, P. E. de Jong, B. H.R. Wolffenbuttel, D. E. Grobbee, A. van Tol, R. P.F. Dullaart, and on behalf of the PREVEND Study Group High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides Eur. Heart J., April 4, 2007; (2007) ehm062v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Thompson, L. S. Wood, E. H. Pickering, B. DeChairo, and C. L. Hyde High-density genotyping and functional SNP localization in the CETP gene J. Lipid Res., February 1, 2007; 48(2): 434 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Tall, L. Yvan-Charvet, and N. Wang The Failure of Torcetrapib: Was it the Molecule or the Mechanism? Arterioscler Thromb Vasc Biol, February 1, 2007; 27(2): 257 - 260. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Borggreve, H. L. Hillege, B. H. R. Wolffenbuttel, P. E. de Jong, M. W. Zuurman, G. van der Steege, A. van Tol, R. P. F. Dullaart, and on behalf of the PREVEND Study Group An Increased Coronary Risk Is Paradoxically Associated with Common Cholesteryl Ester Transfer Protein Gene Variations That Relate to Higher High-Density Lipoprotein Cholesterol: A Population-Based Study J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3382 - 3388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barter and J. J.P. Kastelein Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease J. Am. Coll. Cardiol., February 7, 2006; 47(3): 492 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Borggreve, H. L. Hillege, B. H. R. Wolffenbuttel, P. E. de Jong, S. J. L. Bakker, G. van der Steege, A. van Tol, R. P. F. Dullaart, and on behalf of the PREVEND Study Group The Effect of Cholesteryl Ester Transfer Protein -629C->A Promoter Polymorphism on High-Density Lipoprotein Cholesterol Is Dependent on Serum Triglycerides J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4198 - 4204. [Abstract] [Full Text] [PDF]
|
|